Stemina Biomarker Discovery settles patent dispute

Madison-based Stemina Biomarker Discovery has reached a settlement in a patent dispute with Metabolon of North Carolina. While terms were not disclosed, the two companies entered into a licensing agreement and dismissed pending patent litigation. Stemina, a stem cell company, is working on a diagnostic blood test for autism and is also using its technology to screen drug compounds and chemicals to see if they cause birth defects. With the agreement, Stemina will now be able to license the technology covered by Metabolon’s patents. Metabolon is a diagnostic products and services company.